Press Releases and Publications
Press Releases
Publications
Galveston firm gets $10 million to study radiation antidote
By MYER LEE The Daily News Dec 13, 2020 Darrell Carney’s company, Chrysalis BioTheraputics, received $10.4 million to continue developing…
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
December 01, 2020 09:10 AM Eastern Standard Time GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the…
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc.,…
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure,…
Drug developed by Galveston scientist to be tested for COVID-19 use
GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems…
TP508 Mitigates Radiation Induced GI Damage
Kantara, C., Moya, S.M., Houchen, C.W., Umar, S., Ullrich, R.L., Singh, P. and Carney, D.H. (2015) Novel regenerative peptide TP508…
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency…
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan…
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
GALVESTON, Texas, Feb. 7, 2017 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy…
Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair
Olszewska-Pazdrak B, McVicar, SD, Rayavara K, Moya SM, Kantara K, Gammarano C, Olszewska P, Fuller GM, Sower LE and Carney…
Chrysalis BioTherapeutics receives $3 million grant for nuclear countermeasure development
GALVESTON, TX, May 2, 2016. Chrysalis BioTherapeutics, Inc. today announced receipt of a $3 million grant from the National Institute…
New drug protects against the deadly effects of nuclear radiation 24 hours after exposure
An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering…
Chrysalis BioTherapeutics' TP508 Reverses Radiation-Induced GI Damage
GALVESTON, Texas, Aug. 18, 2015 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced publication of data demonstrating that TP508, the company’s lead drug…
Clinical Trials - Tissue Repair
a. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Fife C, Mader JT, Stone…
Restoration of Endothelial and Myocardial Function by Injection of TP508
a. TP508 (Chrysalin) reverses endothelial dysfunction and increases perfusion and myocardial function in hearts with chronic ischemia. Fossum TW, Olszewska-Pazdrak B,…
Mitigation of Radiation-Induced Vascular Damage
a. Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair. Olszewska-Pazdrak B, McVicar…
TP508 Mode of Action
a. Thrombin peptide TP508 stimulates rapid nitric oxide production in human endothelial cells. Olszewska-Pazdrak B, Hart-Vantassell A, Carney DH. J Vasc Res.…
TP508 Mitigates Radiation Induced GI Damage
Kantara, C., Moya, S.M., Houchen, C.W., Umar, S., Ullrich, R.L., Singh, P. and Carney, D.H. (2015) Novel regenerative peptide TP508…
Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair
Olszewska-Pazdrak B, McVicar, SD, Rayavara K, Moya SM, Kantara K, Gammarano C, Olszewska P, Fuller GM, Sower LE and Carney…